PDS Biotechnology (NASDAQ:PDSB) Downgraded by StockNews.com to “Sell”

PDS Biotechnology (NASDAQ:PDSB) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Saturday.

Several other equities analysts have also commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of PDS Biotechnology in a research report on Thursday, October 24th. Alliance Global Partners upgraded shares of PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $14.25.

PDS Biotechnology Stock Performance

Shares of PDSB stock opened at $3.29 on Friday. PDS Biotechnology has a 12-month low of $2.53 and a 12-month high of $6.85. The business’s fifty day simple moving average is $3.25 and its 200-day simple moving average is $3.28. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.45. The company has a market cap of $121.14 million, a PE ratio of -2.70 and a beta of 1.93.

PDS Biotechnology (NASDAQ:PDSB) last announced its earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same period last year, the business earned ($0.37) EPS. Analysts expect that PDS Biotechnology will post -1.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Tempus Wealth Planning LLC purchased a new stake in PDS Biotechnology in the second quarter valued at approximately $55,000. Ground Swell Capital LLC purchased a new position in PDS Biotechnology during the 2nd quarter worth approximately $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in PDS Biotechnology during the 2nd quarter valued at approximately $115,000. Squarepoint Ops LLC purchased a new stake in shares of PDS Biotechnology in the 2nd quarter valued at $120,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of PDS Biotechnology in the second quarter worth $146,000. 26.84% of the stock is currently owned by hedge funds and other institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.